Fludarabine-based cytoreductive regimen and T-cell-depleted grafts from alternative donors for the treatment of high-risk patients with Fanconi anaemia.
about
Alternative donor transplant of benign primary hematologic disordersThe inherited bone marrow failure syndromesSquamous cell carcinomas of the head and neck in Fanconi anemia: risk, prevention, therapy, and the need for guidelinesLate graft failure in FA--case report and review of the literature.Allogeneic hematopoietic stem cell transplantation for inherited bone marrow failure syndromes.Fertility recovery and pregnancy after allogeneic hematopoietic stem cell transplantation in Fanconi anemia patients.Legionella jordanis in hematopoietic SCT patients radiographically mimicking invasive mold infection.Treatment of Fanconi anemia patients using fludarabine and low-dose TBI, followed by unrelated donor hematopoietic cell transplantation.Stem cell gene therapy for fanconi anemia: report from the 1st international Fanconi anemia gene therapy working group meeting.Chromosomal aberrations associated with clonal evolution and leukemic transformation in fanconi anemia: clinical and biological implications.Preemptive Bone Marrow Transplantation for FANCD1/BRCA2Cyclophosphamide-based in vivo T-cell depletion for HLA-haploidentical transplantation in Fanconi anemia.Late effects in patients with Fanconi anemia following allogeneic hematopoietic stem cell transplantation from alternative donors.Fanconi anemia: a signal transduction and DNA repair pathway.Finding the needle in the hay stack: hematopoietic stem cells in Fanconi anemia.Stress and DNA repair biology of the Fanconi anemia pathwayFanconi anemia - learning from children.Acquisition of Relative Interstrand Crosslinker Resistance and PARP Inhibitor Sensitivity in Fanconi Anemia Head and Neck Cancers.Hematopoietic cell transplantation in Fanconi anemia: current evidence, challenges and recommendations.How I manage patients with Fanconi anaemia.Allogeneic hematopoietic stem cell transplantation for nonmalignant hematologic disorders using chemotherapy-only cytoreductive regimens and T-cell-depleted grafts from human leukocyte antigen-matched or -mismatched donorsSuccessful Outcome With Fludarabine-Based Conditioning Regimen for Hematopoietic Stem Cell Transplantation From Related Donor in Fanconi Anemia: A Single Center Experience From Turkey.Antibody response to human papillomavirus vaccination and natural exposure in individuals with Fanconi Anemia.Excellent outcome of allogeneic bone marrow transplantation for Fanconi anemia using fludarabine-based reduced-intensity conditioning regimen.Recent advances in understanding hematopoiesis in Fanconi Anemia.Radiation-free, alternative-donor HCT for Fanconi anemia patients: results from a prospective multi-institutional study.Sequential strategy for umbilical cord blood transplantation in a Korean Fanconi anemia girl with refractory acute myelomonocytic leukemia and complex karyotype.Four decades of stem cell transplantation for Fanconi anaemia in the Netherlands.Stem cells: biologics for regeneration.Azacitidine as a bridge to allogeneic hematopoietic cell transplantation in a pediatric patient with Fanconi anemia and acute myeloid leukemia.
P2860
Q26823398-9BFD4404-F962-4A6E-B197-0AC2A0FC637FQ26999046-3B1F14AE-DE79-49C1-BEE0-36660A3D0DB6Q27686904-77356CC6-5C34-47F2-9F06-67E31F257FC1Q33401362-93572BE4-6462-4B5E-8B9D-2467C65A635CQ33430004-DB5960AE-298D-4479-B788-94AB25FEA4EAQ34166608-87D81B3C-1394-4025-A9A9-794108ED7F3AQ34185101-11692163-E6BC-4EBF-BC88-CAF9B496CEE3Q34292970-36154735-4F53-4490-A8B0-01B942EC586AQ35086128-ED792423-43F6-4936-AA80-4C5143EA7B5FQ36004687-3F15C167-9A43-440F-BF68-6099C8F01741Q36055207-4D247E4C-5A7F-478C-8727-D57F1041734FQ36754109-C3BC1F00-E19A-4E82-9866-72BF6BFE9772Q37143051-A2659E1D-E3F9-4697-A6B5-2831948614EDQ37358559-82BBCBA8-DFD7-482E-B6E9-753B2E05B824Q37512640-AA179703-0027-44E2-A2C4-5EED9C43A1FFQ38252562-31072BD0-08D8-4033-B547-5F1D9A1C25D2Q38912226-AF4CA8CB-49DF-40DE-86F3-85854659F1F0Q38917809-47946688-048A-4672-9B83-9831A55E7512Q39032775-9BD8A844-A919-40BF-B8D2-A991756758DEQ39285296-3F6F12FE-F478-40AE-873B-B9331470BA86Q39313203-6E86C056-381E-4189-B145-4AFDA435B1ADQ41022642-9347F626-F841-4EE5-A746-CA1B72D255CAQ43168107-694BC498-B82C-4816-8645-98689872A636Q43819705-74647344-1D46-4FD0-AF64-F746B35359C0Q48109237-72124829-839D-4C00-BFD0-98B37E316369Q48260216-210479D5-3DE2-45B7-934A-B986814FCFAAQ48901253-C597E177-E36B-45C7-AC18-87DAAC2C9617Q52984834-34FED0E3-1613-45C0-8DB6-C4CB3C3A20DFQ53460258-4D6D397D-860A-4768-B048-5695D52CDA9EQ54307521-5E2E3B8D-7413-4072-85BC-3E3C6D0A097A
P2860
Fludarabine-based cytoreductive regimen and T-cell-depleted grafts from alternative donors for the treatment of high-risk patients with Fanconi anaemia.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Fludarabine-based cytoreductiv ...... patients with Fanconi anaemia.
@en
Fludarabine-based cytoreductiv ...... patients with Fanconi anaemia.
@nl
type
label
Fludarabine-based cytoreductiv ...... patients with Fanconi anaemia.
@en
Fludarabine-based cytoreductiv ...... patients with Fanconi anaemia.
@nl
prefLabel
Fludarabine-based cytoreductiv ...... patients with Fanconi anaemia.
@en
Fludarabine-based cytoreductiv ...... patients with Fanconi anaemia.
@nl
P2093
P2860
P1476
Fludarabine-based cytoreductiv ...... patients with Fanconi anaemia.
@en
P2093
Andromachi Scaradavou
Farid Boulad
Glenn Heller
Richard J O'Reilly
Sonali Chaudhury
Susan E Prockop
Suzanne Wolden
Trudy N Small
P2860
P304
P356
10.1111/J.1365-2141.2007.06975.X
P407
P577
2008-03-01T00:00:00Z